Xencor, Inc. (XNCR)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 21.27 |
| Open | 21.33 |
| Bid | 21.61 x 100 |
| Ask | 21.67 x 100 |
| Day's range | 21.33 - 22.39 |
| 52-week range | 16.49 - 26.84 |
| Volume | |
| Avg. volume | 602,883 |
| Market cap | 1.335B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.17 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.91 |
Simply Wall St.Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
Business WireXencor Regains CD20 x CD3 Bispecific T-Cell Engager
PASADENA, Calif., June 13, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize
Simply Wall St.Xencor First Quarter 2024 Earnings: Misses Expectations
Xencor ( NASDAQ:XNCR ) First Quarter 2024 Results Key Financial Results Revenue: US$12.8m (down 33% from 1Q 2023). Net...
© 2024 Yahoo. All rights reserved.